butyrolactone I

selective inhibitor of cdk2 & cdc2 kinase; structure given in first source

Also Known As:

alpha-oxo-beta-(4-hydroxyphenyl)-gamma-(4-hydroxy-m-3,3-dimethylallylbenzyl)-gamma-methoxycarbonyl-gamma-butyrolactone

Networked: 18 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Lactones: 1549
  - 4-Butyrolactone: 81
    - butyrolactone I: 18
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Furans: 85
    - 4-Butyrolactone: 81
      - butyrolactone I: 18

Experts

1.	Zhang, Yi: 2 articles (02/2022 - 01/2021)
2.	Xie, Chun-Lan: 2 articles (12/2021 - 06/2018)
3.	Yang, Xian-Wen: 2 articles (12/2021 - 06/2018)
4.	Hong, Pengzhi: 1 article (02/2022)
5.	Kalueff, Allan V: 1 article (02/2022)
6.	Liang, Jinyue: 1 article (02/2022)
7.	Liu, Yayue: 1 article (02/2022)
8.	Ma, Xiaoxiang: 1 article (02/2022)
9.	Nie, Yingying: 1 article (02/2022)
10.	Qian, Zhongji: 1 article (02/2022)

Related Diseases

1.	Insulin Resistance 10/23/2020 - "In this study, we synthesized six racemic butenolide derivatives (namely BL-1-BL-6) by modifying the C-4 side chain of butyrolactone I. Among them, BL-3 and BL-5 improved the insulin resistance of HepG2 cells and did not affect the proliferation of RIN-m5f cell line, which indicated the efficacy and safety of BL-3 and BL-5. "
2.	Inflammation (Inflammations) 01/01/2021 - "Herein, we assessed the anti-inflammatory and intestinal barrier protective effects of butyrolactone-I (BTL-1), derived from the coral-derived endophytic fungus (Aspergillus terreus), using the LPS-induced IPEC-J2 inflammation model and the DSS-induced IBD model in mice. " 10/20/2022 - "Butyrolactone I attenuates inflammation in murine NASH by inhibiting the NF-κB signaling pathway." 02/07/2022 - "Butyrolactone I (BTL-I), a marine fungal metabolite, was previously reported as an in vitro neuroprotectant and inflammation inhibitor. " 02/07/2022 - "Marine fungal metabolite butyrolactone I prevents cognitive deficits by relieving inflammation and intestinal microbiota imbalance on aluminum trichloride-injured zebrafish."
3.	Colorectal Neoplasms (Colorectal Cancer) 12/01/2000 - "In this study, we found that butyrolactone I, a specific inhibitor of CDC2 family kinases, blocks the X-ray- or doxorubicin-induced apoptosis of DLD1 (p21+/+) human colorectal carcinoma cells in a dose-dependent manner. "
4.	Hepatocellular Carcinoma (Hepatoma) 11/01/1998 - "In the present study, the effect of butyrolactone I on expression of the albumin and alpha-fetoprotein (AFP) genes was investigated in HuH-7 human hepatoma cells. " 11/01/1998 - "Suppression of albumin and alpha-fetoprotein gene expression by butyrolactone I, a selective inhibitor of the cdk family, in HuH-7 human hepatoma cells."
5.	Type 2 Diabetes Mellitus (MODY) 11/01/2019 - "The aim of this study was to evaluate the effects of butyrolactone-I (A6) on type 2 diabetes (T2D) in db/db mice because A6 was found to inhibit α-glucosidase activities and TNF-α release, which were associated with improving T2D. " 11/01/2019 - "Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice." 11/01/2019 - "Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice."

Related Drugs and Biologics

1.	butenolide
2.	Phosphotransferases (Kinase)
3.	Glucosidases
4.	Doxorubicin (Adriamycin)
5.	alpha-Fetoproteins (alpha-Fetoprotein)
6.	Albumins
7.	Cyclin-Dependent Kinases (cdk Proteins)
8.	Neuroprotective Agents
9.	Cyclins
10.	Peptide Hydrolases (Proteases)